{"altmetric_id": 81898802, "counts": {"readers": {"citeulike": "0", "mendeley": "76", "connotea": "0"}, "total": {"posts_count": 42}, "twitter": {"unique_users_count": 34, "posts_count": 37}, "blogs": {"unique_users_count": 1, "unique_users": [60332], "posts_count": 2}, "patent": {"unique_users_count": 3, "unique_users": ["patent:US-10787501-B1", "patent:US-10954289-B1", "patent:US-10975139-B1"], "posts_count": 3}}, "citation": {"altmetric_jid": "532721422a83ee84788b4567", "authors": ["Seydoux, Emilie", "Homad, Leah J.", "MacCamy, Anna J.", "Parks, K. Rachael", "Hurlburt, Nicholas K.", "Jennewein, Madeleine F.", "Akins, Nicholas R.", "Stuart, Andrew B.", "Wan, Yu-Hsin", "Feng, Junli", "Nelson, Rachael E.", "Singh, Suruchi", "Cohen, Kristen W.", "McElrath, M. Juliana", "Englund, Janet A.", "Chu, Helen Y.", "Pancera, Marie", "McGuire, Andrew T.", "Stamatatos, Leonidas"], "doi": "10.1101/2020.05.12.091298", "first_seen_on": "2020-05-13T05:19:05+00:00", "issns": [], "journal": "bioRxiv", "last_mentioned_on": 1618272000, "links": ["https://www.biorxiv.org/content/10.1101/2020.05.12.091298v1", "http://biorxiv.org/cgi/content/short/2020.05.12.091298v1?rss=1&utm_source=dlvr.it&utm_medium=twitter", "https://doi.org/10.1101/2020.05.12.091298", "http://dx.doi.org/10.1101/2020.05.12.091298"], "pdf_url": "https://www.biorxiv.org/content/biorxiv/early/2020/05/12/2020.05.12.091298.full.pdf", "pmid": "32511342", "publisher": "Cold Spring Harbor Laboratory", "title": "Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual", "type": "article", "mendeley_url": "https://www.mendeley.com/catalogue/bc0c9c7a-d900-395e-bac9-41b497d2a9e8/"}, "altmetric_score": {"score": 28.28, "score_history": {"1y": 25.43, "6m": 3, "3m": 3, "1m": 0, "1w": 0, "6d": 0, "5d": 0, "4d": 0, "3d": 0, "2d": 0, "1d": 0, "at": 28.28}, "context_for_score": {"all": {"total_number_of_other_articles": 17709629, "mean": 9.4408698303018, "rank": 860842, "this_scored_higher_than_pct": 95, "this_scored_higher_than": 16852562, "rank_type": "exact", "sample_size": 17709629, "percentile": 95}, "similar_age_3m": {"total_number_of_other_articles": 286350, "mean": 20.159378704382, "rank": 25565, "this_scored_higher_than_pct": 91, "this_scored_higher_than": 260794, "rank_type": "exact", "sample_size": 286350, "percentile": 91}, "this_journal": {"total_number_of_other_articles": 120900, "mean": 13.89449139785, "rank": 10888, "this_scored_higher_than_pct": 91, "this_scored_higher_than": 110062, "rank_type": "exact", "sample_size": 120900, "percentile": 91}, "similar_age_this_journal_3m": {"total_number_of_other_articles": 8386, "mean": 19.129678511805, "rank": 838, "this_scored_higher_than_pct": 90, "this_scored_higher_than": 7548, "rank_type": "exact", "sample_size": 8386, "percentile": 90}}}, "demographics": {"poster_types": {"member_of_the_public": 20, "researcher": 11, "practitioner": 1, "science_communicator": 2}, "users": {"twitter": {"cohorts": {"Members of the public": 20, "Scientists": 11, "Practitioners (doctors, other healthcare professionals)": 1, "Science communicators (journalists, bloggers, editors)": 2}}, "mendeley": {"by_status": {"Student  > Postgraduate": 2, "Professor > Associate Professor": 2, "Researcher": 13, "Student  > Master": 7, "Student  > Ph. D. Student": 8, "Professor": 1, "Student  > Bachelor": 12, "Student  > Doctoral Student": 2, "Lecturer": 1, "Other": 5, "Librarian": 2, "Unspecified": 2}, "by_discipline": {"Medicine and Dentistry": 20, "Social Sciences": 1, "Pharmacology, Toxicology and Pharmaceutical Science": 1, "Environmental Science": 1, "Unspecified": 2, "Chemical Engineering": 1, "Engineering": 2, "Economics, Econometrics and Finance": 1, "Immunology and Microbiology": 8, "Computer Science": 1, "Agricultural and Biological Sciences": 6, "Nursing and Health Professions": 3, "Biochemistry, Genetics and Molecular Biology": 8}}}, "geo": {"twitter": {"US": 15, "IN": 1, "GB": 1, "NL": 1, "AU": 2, "KP": 1, "FR": 1, "NP": 1, "CN": 1}}}, "posts": {"twitter": [{"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1949132852"}, "tweet_id": "1260439340393664512"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1054460958226157568"}, "tweet_id": "1260439341421248514"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "389104963"}, "tweet_id": "1260439980264099842"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "2945386099"}, "tweet_id": "1260440320506028032"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1053216952540323840"}, "tweet_id": "1260440390307663878"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "738023789439635457"}, "tweet_id": "1260458009064587264"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "4416084738"}, "tweet_id": "1260458865809928199"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "17106884"}, "tweet_id": "1260477598884409351"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1151583407572307968"}, "tweet_id": "1260538063756771328"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1260538478699384832"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1260538560689643522"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1095912457615269888"}, "tweet_id": "1260580694885052417"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1415091"}, "tweet_id": "1260581823492603906"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "394276145"}, "tweet_id": "1260582428562817025"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "159316065"}, "tweet_id": "1260584513056509954"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "3187144393"}, "tweet_id": "1260585523976036353"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "379388778"}, "tweet_id": "1260586955512954880"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "911591183733760005"}, "tweet_id": "1260593112688111621"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "124093149"}, "tweet_id": "1260593214320328705"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "929582049580564481"}, "tweet_id": "1260599322971828227"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "267932224"}, "tweet_id": "1260611316680548353"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1225799093164752897"}, "tweet_id": "1260622044602892289"}, {"license": "gnip", "citation_ids": [81687333, 81898802], "author": {"tweeter_id": "1154704679328260096"}, "tweet_id": "1260622061313167361"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "143392664"}, "tweet_id": "1260678594524786690"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1034202233309605888"}, "tweet_id": "1260700473826242561"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1118320478257422338"}, "tweet_id": "1260709236817817602"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "2467226497"}, "tweet_id": "1260749090670796802"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1035827399462506496"}, "tweet_id": "1260814368465289217"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "2761450992"}, "tweet_id": "1260826639312748545"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1909488157"}, "tweet_id": "1260922867996385280"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "65261484"}, "tweet_id": "1260958406321467392"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "190087087"}, "tweet_id": "1261842831175385088"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1151599369465946112"}, "tweet_id": "1263153145326133249"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "720658316"}, "tweet_id": "1263205568631590912"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1263435409402494976"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "4901919879"}, "tweet_id": "1263435454466179073"}, {"license": "gnip", "citation_ids": [81898802], "author": {"tweeter_id": "1265336030833422337"}, "tweet_id": "1270041189534724106"}], "blogs": [{"title": "Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19", "url": "https://www.cell.com/cell/fulltext/S0092-8674(20)31008-4?rss=yes", "license": "public", "citation_ids": [82566104, 86713665, 86194527, 85697756, 81822232, 85823596, 87143200, 82123095, 81898802, 76606927, 88246964, 82566104, 86194527, 88246964], "posted_on": "2020-08-14T00:00:00+00:00", "summary": "Sekine et\u00a0al. provide a functional and phenotypic map of SARS-CoV-2-specific T\u00a0cells across the full spectrum of exposure, infection, and COVID-19 severity. They observe that SARS-CoV-2 elicits broadly directed and functionally replete memory T cells that", "author": {"name": "Cell", "url": "http://www.cell.com/cell/current", "description": "Cell RSS feed. For more than 30 years, top international researchers have relied on Cell to publish high impact papers that have come to form the foundation of contemporary life science research.  Founded by Benjamin Lewin (author of Genes), Cell remains at the forefront of exciting developments in biology, continually redefining the important areas of science with cutting edge papers. Published biweekly, Cell includes original research articles of exceptional significance in areas including molecular biology, biochemistry, cancer research, cell biology, developmental biology, genetics, immunology, microbiology, neurobiology, plant biology, structural biology and virology. Submitted articles are reviewed rapidly for both technical quality and general interest, and, if accepted, are published within eight weeks. Cell features topical minireview and review articles in which noted scientists discuss current progress in all areas of the life sciences. Cell also publishes commentaries, meeting reviews, letters to the editor, and book reviews, as well as Positions Available and listings of Conferences and Courses.Visit the Cell website to find out more -  http://www.cell.com."}}, {"title": "Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology", "url": "https://www.cell.com/cell/fulltext/S0092-8674(20)31234-4?rss=yes", "license": "public", "citation_ids": [94064911, 94058534, 77720099, 78284411, 88386380, 84279743, 94018867, 94059428, 82125287, 83673704, 72860025, 85642566, 81898802, 85246037, 90396209, 90396209], "posted_on": "2020-09-16T00:00:00+00:00", "summary": "Serological analyses of \u223c650 SARS-CoV-2-exposed individuals show that 90% of the serum or plasma neutralizing activity targets the virus receptor-binding domain, with structural insights revealing how distinct types of neutralizing antibodies targeting the", "author": {"name": "Cell", "url": "http://www.cell.com/cell/current", "description": "Cell RSS feed. For more than 30 years, top international researchers have relied on Cell to publish high impact papers that have come to form the foundation of contemporary life science research.  Founded by Benjamin Lewin (author of Genes), Cell remains at the forefront of exciting developments in biology, continually redefining the important areas of science with cutting edge papers. Published biweekly, Cell includes original research articles of exceptional significance in areas including molecular biology, biochemistry, cancer research, cell biology, developmental biology, genetics, immunology, microbiology, neurobiology, plant biology, structural biology and virology. Submitted articles are reviewed rapidly for both technical quality and general interest, and, if accepted, are published within eight weeks. Cell features topical minireview and review articles in which noted scientists discuss current progress in all areas of the life sciences. Cell also publishes commentaries, meeting reviews, letters to the editor, and book reviews, as well as Positions Available and listings of Conferences and Courses.Visit the Cell website to find out more -  http://www.cell.com."}}], "patent": [{"title": "Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments", "url": "https://app.dimensions.ai/details/patent/US-10787501-B1", "license": "public", "citation_ids": [81686823, 79886706, 83946256, 81839528, 81950522, 78627096, 82099898, 84234572, 82123095, 81432678, 81687333, 84590251, 82776439, 82125287, 83554448, 81899235, 84064023, 82227840, 82300885, 80174942, 82527991, 99920692, 81757531, 82060698, 84573721, 81625616, 85059707, 82124185, 82449157, 82595199, 82372636, 83326754, 83146578, 82236864, 81550014, 82750447, 78284411, 50982232, 83947308, 4498119, 82312840, 82447592, 82059207, 83819478, 83493208, 82526969, 83325716, 82683654, 83490745, 83816209, 76759624, 82241906, 82006689, 82127390, 83471779, 81898802, 82752495, 83470627, 82595623, 82918542, 82373603, 81317927, 84026513, 79411573, 82846613, 84064050, 82136174, 82398872, 82371737, 82526610, 78206570, 82592966, 82006659, 80912392, 78976480, 89122343, 89309738, 92789824, 93046290, 42295981, 2000877, 4443560, 1927968, 4498119, 80912392], "posted_on": "2020-09-29T00:00:00+00:00", "summary": "The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infecti", "ucid": "US-10787501-B1", "jurisdiction": "US", "filing_status": "Grant"}, {"title": "Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments", "url": "https://app.dimensions.ai/details/patent/US-10954289-B1", "license": "public", "citation_ids": [81687333, 84590251, 83554448, 81899235, 84064023, 82227840, 82300885, 80174942, 82527991, 81686823, 79886706, 99920692, 81757531, 82060698, 84573721, 81625616, 85059707, 82124185, 82449157, 82595199, 82372636, 83326754, 83146578, 82236864, 83946256, 81550014, 82750447, 78284411, 50982232, 83947308, 4498119, 82312840, 82447592, 82059207, 83819478, 83493208, 82526969, 83325716, 82683654, 83490745, 82776439, 82125287, 83816209, 76759624, 4225088, 82241906, 82006689, 82127390, 84234572, 82123095, 81839528, 83471779, 81898802, 82752495, 83470627, 82595623, 82918542, 82373603, 81317927, 84026513, 79411573, 81331345, 82846613, 84064050, 82136174, 81432678, 81950522, 78627096, 82099898, 82398872, 82371737, 82526610, 78206570, 82592966, 82006659, 80912392, 78976480, 89122343, 76348331, 78651983, 89309738, 86397980, 92789824, 83360939, 93046290, 42295981, 83349805, 84959013, 2000877, 79801422, 76810504, 4443560, 82104617, 1927968, 4498119, 80912392], "posted_on": "2021-03-23T00:00:00+00:00", "summary": "The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infecti", "ucid": "US-10954289-B1", "jurisdiction": "US", "filing_status": "Grant"}, {"title": "Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments", "url": "https://app.dimensions.ai/details/patent/US-10975139-B1", "license": "public", "citation_ids": [81687333, 84590251, 83554448, 81899235, 84064023, 82227840, 82300885, 80174942, 82527991, 81686823, 79886706, 99920692, 81757531, 82060698, 84573721, 81625616, 85059707, 82124185, 82449157, 82595199, 83326754, 83146578, 82236864, 83946256, 81550014, 82750447, 78284411, 50982232, 83947308, 4498119, 82312840, 82447592, 82059207, 83819478, 83493208, 82526969, 83325716, 82683654, 83490745, 82776439, 82125287, 83816209, 76759624, 82241906, 82006689, 82127390, 84234572, 82123095, 81839528, 83471779, 81898802, 82752495, 4225088, 83470627, 82595623, 82918542, 82373603, 81317927, 84026513, 81331345, 82846613, 84064050, 82136174, 81432678, 81950522, 78627096, 82099898, 82398872, 82371737, 82526610, 78206570, 82592966, 82006659, 80912392, 78976480, 89122343, 76348331, 78651983, 89309738, 86397980, 92789824, 83360939, 93046290, 42295981, 83349805, 84959013, 2000877, 79801422, 76810504, 4443560, 82104617, 1927968, 4498119, 80912392], "posted_on": "2021-04-13T00:00:00+00:00", "summary": "The present disclosure provides antibodies and antigen-binding fragments thereof that bind specifically to a coronavirus spike protein and methods of using such antibodies and fragments for treating or preventing viral infections (e.g., coronavirus infecti", "ucid": "US-10975139-B1", "jurisdiction": "US", "filing_status": "Grant"}]}, "score": 28.28, "images": {"small": "https://badges.altmetric.com/?size=64&score=29&types=abtttttt", "medium": "https://badges.altmetric.com/?size=100&score=29&types=abtttttt", "large": "https://badges.altmetric.com/?size=180&score=29&types=abtttttt"}}